PolyPid (PYPD) Q4 2025 earnings summary

Executive summary

• Completed SHIELD II Phase III trial with D-PLEX100 meeting all primary and key secondary endpoints, showing significant reduction in surgical site infections.

• Advanced D-PLEX100 to final regulatory preparation, with positive FDA pre-NDA feedback supporting a rolling NDA submission expected by end of Q1 2026.

• Progressed U.S. commercial partnership discussions to advanced stages, reflecting strong clinical data and market need.

• Introduced Kynatrix technology, expanding drug delivery capabilities into new therapeutic areas, including metabolic diseases.

• Appointed Brooke Story as chairman of the board, enhancing governance and leadership.

Financial highlights

• Q4 2025 R&D expenses were $6.2M, down from $7M year-over-year, reflecting trial completion.

• Q4 2025 net loss was $8.5M ($0.41/share), unchanged from prior year but with lower per-share loss.

• Full-year 2025 net loss was $34.2M ($2.09/share), up from $29M ($4.91/share) in 2024.

• Full-year 2025 R&D expenses rose to $23.8M from $22.8M, driven by trial and regulatory activities.

• G&A expenses increased to $1.8M in Q4 2025 (from $1M) and $7.2M for the year (from $4.3M), mainly due to non-cash PSU vesting.

Outlook and guidance

• Rolling NDA submission for D-PLEX100 to begin by end of Q1 2026, with FDA review expected to be shortened to 6 months due to Fast Track and Breakthrough Therapy Designation.

• Existing cash resources expected to fund operations into the second half of 2026 and through key milestones.

• Focus remains on U.S. commercialization, with European submission planned after FDA filing.